All In Biotech

NDA 021516 · Bausch and Lomb

Istalol

Timolol Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jun 4, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

306

98 Phase 3, 14 recruiting

FAERS reports

7,905

3,740 serious, 443 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2024.

Timolol Maleate Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Timolol Maleate Ophthalmic Solution is a beta adrenergic blocker indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. ( 1 )

Mechanism: Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic receptor blockade in the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ISTALOL · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2

Clinical trials

Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure982
  • drug ineffective588
  • eye pain453
  • fatigue421
  • eye irritation374
  • dizziness299
  • diarrhoea293
  • vision blurred271
  • nausea268
  • off label use267
  • headache257
  • dyspnoea242

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004158
2005194
2006157
2007144
2008136
2009141
2010210
2011222
2012330
2013122
2014147
2015259
2016314
2017351
2018370
2019408
20201,444
2021417
2022440
2023514
2024518
2025558
2026350

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Istalol (Timolol Maleate)

2024 spending

$652K

Beneficiaries

323

1,279 claims

Per beneficiary

$2,019

$78.54 per unit

View as table
YearSpending
2020$3,691,633
2021$1,480,757
2022$1,046,998
2023$803,317
2024$652,073

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,308 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.